Seres Therapeutics begins phase 1b trial of SER-301 in ulcerative colitis
Seres Therapeutics has dosed the first patient in a phase 1b clinical trial, which is assessing SER-301 for the treatment of active mild-to-moderate ulcerative colitis (UC). According to the US-based biotech company, SER-301 is an oral fermented microbiome therapeutic designed for dampening the unusual gastrointestinal inflammation central to ulcerative colitis and promote clinical remission in […]
VirTrial, a US bioscience technology company, has been selected by Canadian biotech company BetterLife Pharma as its telehealth platform provider of choice for launching COVID-19 clinical trials. The partnership will help BetterLife Pharma to carry out remote patient monitoring for its upcoming COVID-19 clinical trials in Australia for evaluating the efficacy of its interferon alpha 2b formulation […]
Continue reading …
Australian drug development company Noxopharm has dosed the first patient in the phase 1 NOXCOVID-1 clinical trial with Veyonda, its lead pipeline candidate, in hospitalized COVID-19 patients. Veyonda is an experimental anti-cancer drug. It is being evaluated in the NOXCOVID-1 clinical trial in the treatment of hospitalized patients with moderate lung dysfunction, who need low […]
Continue reading …
Kazia Therapeutics, an Australian biotech company, has secured the rare pediatric disease designation (RPDD) for paxalisib (formerly GDC-0084) from the US Food and Drug Administration (FDA) for the treatment of diffuse intrinsic pontine glioma (DIPG). Diffuse intrinsic pontine glioma is considered to be a rare and highly-aggressive childhood brain cancer. The rare pediatric disease designation […]
Continue reading …
Noxopharm, an Australian clinical-stage pharma company, has started the phase 1 NOXCOVID-1 clinical trial for Veyonda in Europe to evaluate the anti-cancer drug candidate as a potential treatment for cytokine storm and septic shock in COVID-19 patients. With a capability to inhibit cGAS-STING signalling, Veyonda can potentially block the start of the cytokine storm which […]
Continue reading …Australian clinical diagnostics company SpeeDx raises $15m in Series B round
February 12, 2020 No Comment
SpeeDx, an Australian clinical diagnostics company, to support improved patient outcomes, has secured $15 million in a Series B funding round from US-based investor Northpond Ventures. The company has developed a molecular diagnostics test portfolio, mainly for infectious diseases, that offers identification and also therapeutic guidance capabilities. Michael P. Rubin – Founder and CEO of […]
Continue reading …
Eli Lilly and Company (Lilly) has initiated the phase 3 LIBRETTO-431 clinical trial to evaluate selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) in patients who are treatment-naïve. The US pharma company is aiming to enroll 400 patients in the late-stage clinical trial. The patients will be grouped randomly to be subjected to […]
Continue reading …
US biotech company Levo Therapeutics has been granted fast track designation for LV-101 (intranasal carbetocin) from the US Food and Drug Administration (FDA) for the treatment of Prader-Willi syndrome (PWS). According to the US National Library of Medicine, Prader-Willi syndrome is a complex genetic condition that impacts several parts of the body. In infancy, Prader-Willi […]
Continue reading …
Collaborative Medicinal Development (CMD) has enrolled the first patient in a placebo-controlled clinical trial to evaluate the safety and efficacy of CuATSM in patients with Amyotrophic Lateral Sclerosis (ALS). The Australian biotech company plans to enroll a total of 80 patients across four clinical sites in Australia. Amyotrophic Lateral Sclerosis is also known as Motor […]
Continue reading …
Australian biotech company Prana Biotechnology has secured Orphan Drug designation for PBT434, its lead molecule, for the treatment of Multiple System Atrophy (MSA). Prana Biotechnology claims that its application was based on the proposed use of the molecule as a treatment for MSA, including the medical and scientific rationale. The Australian biotech company said that […]
Continue reading …
Business News Today
- Dam Nai wind farm Vietnam to be acquired by SN Power
- TRATON to take full ownership of US truck manufacturer Navistar for $3.7bn
- Elizabeth River Tunnels Project : Skanska to sell 50% stake for $625m
- Spanish proptech company Clikalia secures investment from Mouro Capital
- Orange Romania to acquire 54% stake in Telekom Romania Communications
- Carlyle Group invests $250m in US e-commerce company Pharmapacks
- Cano Health to merge with blank check company Jaws Acquisition in $4.4bn deal
- Naturgy to sell stake in Chilean utility CGE to China’s SGI for €2.5bn
- Arthur J. Gallagher acquires wholesale insurance broker AWIS Group
- Hub acquires insurance brokerage assets of Larry Dean Massey, Jr.
